<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Earnings prospects on FinanClub</title>
    <link>https://finan.club/tags/earnings-prospects/</link>
    <description>Recent content in Earnings prospects on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 09 Jan 2024 09:02:57 +0000</lastBuildDate><atom:link href="https://finan.club/tags/earnings-prospects/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Tue, 09 Jan 2024 09:02:57 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:29
Chances: ImmunoGen has recently been upgraded to a Zacks Rank #1 (Strong Buy), indicating growing optimism about its earnings prospects. The company&amp;rsquo;s pipeline includes promising candidates such as Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151, which bodes well for its future growth potential.</description>
    </item>
    
    <item>
      <title>NIO</title>
      <link>https://finan.club/us/nio/</link>
      <pubDate>Tue, 12 Dec 2023 14:46:28 +0000</pubDate>
      
      <guid>https://finan.club/us/nio/</guid>
      <description>score:84
Chances: Nio management provided significant insights into the direction of the business. The average of price targets set by Wall Street analysts indicates a potential upside of 64.2% in NIO Inc. (NIO). NIO Inc. (NIO) might move higher on growing optimism about its earnings prospects.</description>
    </item>
    
  </channel>
</rss>
